AONs are a promising therapeutic tool, as was recently shown by phase I and phase I/II clinical trials in Duchenne muscular dystrophy (DMD) boys carrying specific deletions in the DMD gene [60]. Here, DMD is linked to Duchenne muscular dystrophy.